Thursday, August 28th, 2025
Stock Profile: ATYR
ATYR Logo

aTyr Pharma, Inc. (ATYR)

Market: NASD | Currency: USD

Address: 10240 Sorrento Valley Road

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA Show more




📈 aTyr Pharma, Inc. Historical Chart






📊 Statistics





💰 Dividend History


Year Annual Yield (%) Total Amount Current Yield (%) Ex Date Pay Date Particulars
2019 - $0.071429 - 2019-07-01 - Stock split
Total Amount for 2019: $0.071429


📅 Earnings & EPS History for aTyr Pharma, Inc.


DateReported EPS
2025-11-06 (estimated upcoming)-
2025-08-07-0.22
2025-05-07-0.17
2025-03-13-0.18
2024-11-07-0.23
2024-08-13-0.23
2024-05-02-0.23
2024-03-14-0.25
2023-11-09-0.2
2023-08-09-0.22
2023-05-09-0.29
2023-03-09-0.26
2022-11-10-0.46
2022-08-15-0.44
2022-05-09-0.44
2022-03-14-0.31
2021-11-10-0.42
2021-08-10-0.64
2021-05-13-0.51
2021-03-23-0.47
2020-11-12-0.68
2020-08-13-0.69
2020-05-120.25
2020-03-26-1.54
2019-11-14-1.47




📰 Related News & Research


No related articles found for "atyr pharma".